東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

An inactivated paramyxovirus vaccine...

Weber, Mary L.

FindBook

Google Book

Amazon

博客來

An inactivated paramyxovirus vaccine in a maternal immunization model does not cause enhanced respiratory disease in the offspring during primary infection.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	An inactivated paramyxovirus vaccine in a maternal immunization model does not cause enhanced respiratory disease in the offspring during primary infection./
作者:	Weber, Mary L.
面頁冊數:	50 p.
附註:	Source: Masters Abstracts International, Volume: 54-06.
Contained By:	Masters Abstracts International54-06(E).
標題:	Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1595523
ISBN:	9781321948493

An inactivated paramyxovirus vaccine in a maternal immunization model does not cause enhanced respiratory disease in the offspring during primary infection.
Weber, Mary L.

An inactivated paramyxovirus vaccine in a maternal immunization model does not cause enhanced respiratory disease in the offspring during primary infection. - 50 p.

Source: Masters Abstracts International, Volume: 54-06.

Thesis (M.S.)--Saint Louis University, 2015.

Respiratory Syncytial Virus (RSV) is a paramyxovirus that is endemic worldwide in pediatric populations. During the first six months of life, infants are at risk of developing sever lower respiratory tract infection from RSV that can develop into bronchiolitis. Currently, there is no licensed vaccine; however, in the 1960s, a formalin-inactivated RSV vaccine failed to protect children against subsequent RSV exposure and resulted in the vaccinated children developing an enhanced respiratory disease (ERD). The vaccine induced the production of non-protective antibodies that complexed with the virus causing immune complexes to deposit in the lungs. FIRSV created an enormous concern for the development of a safe and efficacious vaccine that does not induce ERD. One of the current target populations for vaccination is women of childbearing age and pregnant women using non-replicating protein subunit vaccines. The goal of maternal immunization is to boost the neutralizing antibody response and provide passive immunity to the infant to protect against bronchiolitis during the first year of life when the immune system is immature.

ISBN: 9781321948493Subjects--Topical Terms:

611031
Immunology.

An inactivated paramyxovirus vaccine in a maternal immunization model does not cause enhanced respiratory disease in the offspring during primary infection.
LDR:02989nmm a2200301 4500 001 2068029
005 20160422125028.5
008 170521s2015 ||||||||||||||||| ||eng d
020 $a 9781321948493
035 $a (MiAaPQ)AAI1595523
035 $a AAI1595523
040 $a MiAaPQ $c MiAaPQ
100 1 $a Weber, Mary L. $3 3182910
245 1 3 $a An inactivated paramyxovirus vaccine in a maternal immunization model does not cause enhanced respiratory disease in the offspring during primary infection.
300 $a 50 p.
500 $a Source: Masters Abstracts International, Volume: 54-06.
500 $a Advisers: Mark R. Buller; Laurie P. Shornick.
502 $a Thesis (M.S.)--Saint Louis University, 2015.
520 $a Respiratory Syncytial Virus (RSV) is a paramyxovirus that is endemic worldwide in pediatric populations. During the first six months of life, infants are at risk of developing sever lower respiratory tract infection from RSV that can develop into bronchiolitis. Currently, there is no licensed vaccine; however, in the 1960s, a formalin-inactivated RSV vaccine failed to protect children against subsequent RSV exposure and resulted in the vaccinated children developing an enhanced respiratory disease (ERD). The vaccine induced the production of non-protective antibodies that complexed with the virus causing immune complexes to deposit in the lungs. FIRSV created an enormous concern for the development of a safe and efficacious vaccine that does not induce ERD. One of the current target populations for vaccination is women of childbearing age and pregnant women using non-replicating protein subunit vaccines. The goal of maternal immunization is to boost the neutralizing antibody response and provide passive immunity to the infant to protect against bronchiolitis during the first year of life when the immune system is immature.
520 $a In this thesis, the effect of a non-replicating, inactivated paramyxoviral vaccine in a maternal immunization model was investigated in offspring given a primary infection with a live paramyxovirus virus, Sendai virus (SeV). It was hypothesized that non-protective antibodies could be generated in the female mice, as a result of immunization with a non-replicating vaccine. The non-protective maternal antibodies can be passively transferred to the offspring and could result in an ERD upon SeV challenge. The SeV vaccine was inactivated using ultra violet light and the female mice were immunized intranasally with 500 pfu/g. The offspring were infected intranasally with 2,000 pfu/g SeV and monitored for ERD. Ultimately, we determined that the ERD was not passively transferred to the offspring as a result of the maternal immunization with an inactivated vaccine.
590 $a School code: 0193.
650 4 $a Immunology. $3 611031
650 4 $a Virology. $3 642304
650 4 $a Microbiology. $3 536250
690 $a 0982
690 $a 0720
690 $a 0410
710 2 $a Saint Louis University. $b Microbiology. $3 3182911
773 0 $t Masters Abstracts International $g 54-06(E).
790 $a 0193
791 $a M.S.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1595523